The 8th IP Forefront Pharma Forum, organized by IP ForeFront, was held in Shanghai from October 18 to 20, 2023. Li Wu, Xilin Zheng, Ying Wang, Jian Yang, Rui Wang, Runzhi Wu, and Jun Hu, partners and senior counsels of Lifang & Partners, attended the forum and held a pre-conference seminar on IP Licensing and Transaction and IPO in Biopharmaceutical Industry.

The seminar was hosted by Li Wu, with speeches by Ying Wang, Jian Yang, Rui Wang, Runzhi Wu, and Jun Hu. The panel discussion centered on From Innovation to IPO: Main Considerations for IP Risk Prevention and Investment, Financing, and Listing of Pharma Enterprises, which was moderated by Xilin Zheng, with the participation of Jun Hu, senior counsel of Lifang & Partners, Liu Shuqin, IP director of Ctm Bio, Wu Chunhua, head of IP department of Henlius, Fan Hongbo, VP of healthcare team of CITIC Securities.

Dr. Li Wu, Partner of Lifang & Partners

Dr. Jian Yang, Senior Counsel of Lifang & Partners

Dr. Runzhi Wu, Senior Counsel of Lifang & Partners

Dr. Rui Wang, Senior Counsel of Lifang & Partners

Jun Hu, Senior Counsel of Lifang & Partners

Ying Wang, Partner of Lifang & Partners

Panel Discussion

Lifang & Partners' life sciences and healthcare team comprises professionals who have represented many clients in the sector from multidisciplinary practices, covering M&A, capital markets, private equity and venture capital investment, intellectual property, compliance and dispute resolution. Some of our team members have worked for leading pharmaceutical companies and regulatory authorities. We combine our past legal experience and comprehensive understanding of today’s industry development to enable our clients to achieve their business objectives.